C
atherosclerosis progression
Imaging & Subclinical DiseaseImaging markerriskpartially modifiable
10
evidence score
Also known as: Atherosclerosis progression (coronary/carotid), atherosclerosis in coronary and carotid vessels
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 3meta-analyses: 0trials: 7genetic: 0MR bonus:
References (1)
0 meta-analyses / systematic reviews- Homocysteine and cardiovascular disease. — Current atherosclerosis reports 2004 · PMID 15023293
Clinical trials (4)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT03542110 | Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial | TERMINATED | INTERVENTIONAL | Alirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection |
| NCT01872845 | A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT | COMPLETED | INTERVENTIONAL | Pravastatin 40mg, Rosuvastatin |
| NCT01681199 | The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease | UNKNOWN | INTERVENTIONAL | Fluvastatin extended release tablet |
| NCT00228176 | Randomized, Multicenter, Double-blind, Placebo-controlled, Two-arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by Carotid Artery Intima-media Thickness (CIMT), in Overweight Patients With Additional Risk Factors | TERMINATED | INTERVENTIONAL | Rimonabant, Placebo (for Rimonabant) |
Genetic associations (0)
None linked.